Nabumetone

Jump to: navigation, search

Synonyms / Brand Names: Nabumetonum, Nabumetona, Arthaxan, Balmox, Consolan, Dolsinal, Flambate, Listran, Mebutan, Nabuser, Prodac, Relafen, Relif, Relifen, Relifex, Unimetone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Dosing and Administration

The recommended starting dose is 1,000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1,500 mg to 2,000 mg per day. RELAFEN can be given in either a single or twice-daily dose. Dosages greater than 2,000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment. Caution should be used in prescribing RELAFEN to patients with moderate or severe renal insufficiency. The maximum starting doses of RELAFEN in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful monitoring of renal function in patients with moderate or severe renal insufficiency, daily doses may be increased to a maximum of 1,500 mg and 1,000 mg, respectively



FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.

Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.

Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.

Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information

Trial Resources
Ongoing Trials, Trial Results

Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.

Media Resources
Slides, Video, Images, MP3, Podcasts, etc.

Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.

International Resources
en Español






FDA Package Insert Resources

Indications

Contraindications

Side Effects

Drug Interactions

Precautions

Overdose

Instructions for Administration

How Supplied

Pharmacokinetics and Molecular Data

FDA label

FDA on Nabumetone

Return to top

Publication Resources

Most Recent Articles on Nabumetone

Review Articles on Nabumetone

Articles on Nabumetone in N Eng J Med, Lancet, BMJ

WikiDoc State of the Art Review

Textbook Information on Nabumetone

Return to top

Trial Resources

Ongoing Trials with Nabumetone at Clinical Trials.gov

Trial Results with Nabumetone

Return to top

Guidelines & Evidence Based Medicine Resources

US National Guidelines Clearinghouse on Nabumetone

Cochrane Collaboration on Nabumetone

Cost Effectiveness of Nabumetone

Return to top

Media Resources

Powerpoint Slides on Nabumetone

Images of Nabumetone

Podcasts & MP3s on Nabumetone

Videos on Nabumetone

Return to top

Patient Resources

Patient Information from National Library of Medicine

Patient Resources on Nabumetone

Discussion Groups on Nabumetone

Patient Handouts on Nabumetone

Blogs on Nabumetone

Nabumetone in the News

Nabumetone in the Marketplace

Return to top


Nabumetone Dosage and Drug Interaction

International Resources

Nabumetone en Español

Return to top


Adapted from the FDA Package Insert.


Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg